China Resources Pharmaceutical Group Ltd (HKEX: 03320) has announced that its wholly-owned subsidiary, China Resources Pharmaceutical Holdings Limited, has completed the public issuance of its second tranche of 2026 corporate bonds in China.

The second tranche of 2026 corporate bonds, with a principal amount of RMB900 million, has been issued with a term of three years and a coupon rate of 1.48% per annum.

The net proceeds raised from the issuance of the second tranche of 2026 corporate bonds will be used for productive expenditures, including repayment of corporate debt, replenishment of working capital, project development and operating expenses, investments related to technological innovation, and other purposes that comply with applicable laws and regulations.